Skip to main content
Premium Trial:

Request an Annual Quote

IntelligentMDx Nets $3M Investment

NEW YORK (GenomeWeb News) – Cambridge, Mass.-based molecular diagnostics company IntelligentMDx has raised $3 million in a financing from two undisclosed investors, the company said on Tuesday.

The company will use the funds to develop tests for specific viral and bacterial nucleic acid targets using a proprietary bioinformatics approach. It makes molecular diagnostic test kits for transplantation, fungal infection, blood screening, meningitis/encephalitis, and respiratory disease.

The company said it raised the $3 million through a Series D preferred stock offering it began on May 12. IntelligentMDx also noted that it has raised a total of $26.5 million through funding from non-venture capital investors since 2004.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.